Immunocore Holdings plc
NASDAQ:IMCRBiotechnology
+$0.18 today
- Market cap
- $1.44B
- Beta
- 0.75
- P/E (TTM)
- -77.5
- EPS (TTM)
- -$0.37
Volume 0.42M
Average 0.40M
IMCR Operating Margin
Operating income as a percentage of revenue, showing the profitability of core operations.
Immunocore Holdings plcNASDAQ: IMCR
Operating Margin · Q1 FY2026 · quarter ended Mar 2026
Operating margin widens to 6.8%
Operating margin was 6.8% in Q1 FY2026, up 10.7 pp from a year earlier. On a trailing-twelve-month basis it was -7.6%, up 6.7 pp year over year. Over 3 fiscal years it widened by 18.3 pp.
Context
- Operating margin widened in 3 of the last 3 fiscal years.
- FY2025 was the highest level in the 4 fiscal years shown.
What to watch
Whether operating margin reaches the consensus estimate from 11 analysts of -33.9% for the fiscal year ending Dec 2026, down from -11.3% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- 6.8%+25.7 pp QoQ
- Last fiscal yearDec 2025
- -11.3%+11.4 pp YoY
- LTMMar 2026
- -7.6%+6.7 pp YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Operating Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -11.3%
- Year-over-year change
- +11.4pp
| Period | Period end | Operating Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -11.3% | +11.4pp |
| FY2024 | 2024-12-31 | -22.7% | — |
| FY2023 | 2023-12-31 | -23.9% | +5.7pp |
| FY2022 | 2022-12-31 | -29.7% | +448.9pp |
| FY2021 | 2021-12-31 | -478.5% | — |
Operating Margin vs competitors
How IMCR compares with its peers on the latest reported figures
- IMCR's LTM Mar 2026 operating margin of -7.6% is the 2nd highest of the 11 companies compared; the peer median is -310.6%.
- Its year-over-year change of +6.7 pp is the 5th highest of 11, against a peer median of -84.8 pp.
- Over three fiscal years its change of +18.3 pp compares with a peer median of -29.5 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 42.3% | +95.9 pp | +514.7 pp | |
| LTM Mar 2026 | -7.6% | +6.7 pp | +18.3 pp | |
| LTM Mar 2026 | -40.5% | +24.7 pp | +32.2 pp | |
| LTM Jun 2026 | -71.8% | -41.3 pp | -95.7 pp | |
| LTM Sep 2026 | -150.2% | +165.7 pp | +146148.2 pp | |
| LTM Jun 2026 | -205.8% | -128.2 pp | -91.2 pp | |
| LTM Jun 2026 | -415.4% | -286.4 pp | +93.7 pp | |
| LTM Mar 2026 | -570.3% | -528.3 pp | -394.4 pp | |
| LTM Mar 2026 | -726.3% | +490.3 pp | -797.6 pp | |
| FY2025 | -1916.9% | -1508.3 pp | -1817.4 pp | |
| FY2025 | -2506.5% | -213.2 pp | +17413.5 pp | |
| Peer median (excluding IMCR) | -310.6% | -84.8 pp | -29.5 pp | |
Competitors are the stored peer set for IMCR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 · GBP | FY2022 Dec 2022 · GBP | FY2023 Dec 2023 · GBP | FY2024 Dec 2024 · USD | FY2025 Dec 2025 · USD |
|---|---|---|---|---|---|
| Revenue | 27.04M | 144.23M | 197.39M | 247.98M | 297.57M |
| Cost of Revenue | 0 | 5.29M | 820.63K | 5.54M | 6.21M |
| Gross Profit | 27.04M | 138.94M | 196.57M | 242.44M | 291.36M |
| Gross Margin | 100.0% | 96.3% | 99.6% | 97.8% | 97.9% |
| Research & Development | 74.31M | 84.31M | 129.42M | 177.44M | 204.47M |
| Selling, General & Admin | 82.15M | 0 | 114.35M | 121.17M | 120.62M |
| Operating Expenses | 156.46M | 181.71M | 243.77M | 298.77M | 325.09M |
| Depreciation & Amortization | 5.63M | 4.41M | 3.24M | 3.36M | 2.43M |
| EBITDA | (123.58M) | (38.35M) | (40.87M) | (38.5M) | 387.18K |
| EBITDA Margin | -457.0% | -26.6% | -20.7% | -15.5% | 0.1% |
| Operating Income | (129.42M) | (42.77M) | (47.2M) | (56.28M) | (33.74M) |
| Operating Margin | -478.5% | -29.7% | -23.9% | -22.7% | -11.3% |
| Interest Income | 65K | 3.76M | 14.23M | 25.62M | 16.48M |
| Interest Expense | 5.57M | 5.41M | 4.08M | 18.84M | 12.17M |
| Other Income / Expenses | (3.92M) | 8.95M | (982.07K) | 14.01M | 19.53M |
| Income Before Tax | (133.34M) | (33.82M) | (48.19M) | (42.32M) | (14.21M) |
| Pre-Tax Margin | -493.0% | -23.4% | -24.4% | -17.1% | -4.8% |
| Income Tax Expense | 111.19K | 9.65M | (4.43M) | (1.48M) | 12.21M |
| Net Income | (133.45M) | (43.46M) | (43.75M) | (40.81M) | (26.42M) |
| Net Margin | -493.4% | -30.1% | -22.2% | -16.5% | -8.9% |
| EPS (Basic) | (3.13) | (0.95) | (0.89) | (1.02) | (0.53) |
| EPS (Diluted) | (3.00) | (0.95) | (0.89) | (1.02) | (0.53) |
| Weighted Avg Shares | 42.49M | 45.71M | 48.89M | 49.99M | 50.35M |
| Weighted Avg Shares (Diluted) | 43.86M | 45.71M | 48.89M | 49.99M | 50.35M |
Immunocore Holdings plc
NASDAQ:IMCR
Intrinsic Alpha fair value
Locked
Current Price
$27.81
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.